Zevra Therapeutics, Inc. reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company achieved a net income of $83.2 million, a substantial turnaround from a net loss of $105.5 million in the previous year. This improvement was primarily driven by a gain of $148.3 million from the sale of a rare pediatric disease priority review voucher (PRV) and a notable increase in revenue, which rose to $106.5 million from $23.6 million in 2024. The revenue growth was largely attributed to increased product sales of its lead product, MIPLYFFA, which accounted for approximately 82% of total revenues.
Zevra's operational metrics also reflected significant changes compared to the previous fiscal period. The company reported a decrease in research and development expenses, which fell from $42.1 million in 2024 to $12.7 million in 2025, largely due to reduced spending on the Phase 2 clinical study for KP1077. Conversely, selling, general, and administrative expenses increased by approximately $22.7 million, reaching $77.6 million, as the company expanded its commercial organization to support the launch of MIPLYFFA and OLPRUVA.
Strategically, Zevra has made notable advancements, including the acquisition of Acer Therapeutics, which was completed on November 17, 2023. This acquisition brought OLPRUVA, an approved treatment for urea cycle disorders, into Zevra's portfolio, along with Acer's pipeline of investigational product candidates, including celiprolol for Vascular Ehlers-Danlos syndrome. The company is actively enrolling patients in a Phase 3 clinical trial for celiprolol, which is expected to address significant unmet needs in this rare disease space.
As of December 31, 2025, Zevra employed 61 full-time staff and reported 161 enrollments for MIPLYFFA under its global expanded access program. The company is pursuing regulatory approval for MIPLYFFA in Europe, having filed a Marketing Authorization Application with the European Medicines Agency in July 2025. Looking ahead, Zevra anticipates continued fluctuations in expenses and revenues as it builds its commercial capabilities and advances its product pipeline. The company remains focused on expanding patient access to its therapies while navigating the complexities of the rare disease market.
About ZEVRA THERAPEUTICS, INC.
Zevra Therapeutics is a biotech company focused on developing and commercializing therapies for rare diseases. Its portfolio includes approved products like AZSTARYS and OLPRUVA, and late-stage candidates such as MIPLYFFA for Niemann-Pick disease type C. The company leverages proprietary technology, strategic acquisitions, and collaborations to address unmet medical needs in niche markets worldwide. Its business model emphasizes innovation, targeted commercialization, and pipeline expansion in the rare disease space.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.